Sanofi SA (LTS:0A2V)
$ 49 0 (0%) Market Cap: 122.85 Bil Enterprise Value: 141.18 Bil PE Ratio: 28.19 PB Ratio: 1.63 GF Score: 87/100

Sanofi SA at Bank of America Merrill Lynch Global Healthcare Conference Transcript

Sep 19, 2019 / 01:30PM GMT
Graham Glyn Charles Parry
BofA Merrill Lynch, Research Division - MD and Head of Healthcare Equity Research

(technical difficulty)

Essentially, I think, it address some of the changes that were needed in the pipeline at the time and before that, he's running the discovery business at Roche out of Basel. So John's got a few slides to go through and just a high-level intro, and then we'll be able to dig straight into Q&A.

And so John, if you'd like to maybe take the podium for the presentation.

John C. Reed
Sanofi - Executive VP and Global Head of Research & Development

Sure. Thanks, Graham. Well, thanks for joining today and like just to provide a bit of a brief overview of some of the ways we're currently attempting to evolve the Sanofi R&D enterprise.

Of course, you have the forward-looking statements [probably].

So really been trying to reshape the agenda for research in a couple of different ways. We, working with the team, looked at where we were as an organization, we saw that we still had some distance

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot